Medicine and Dentistry
Acute Appendicitis
15%
Adenocarcinoma
9%
Appendix Tumor
9%
Biliary Atresia
7%
Bilirubin
7%
CA-125
22%
Cancer
18%
Carcinomatous Peritonitis
22%
Clinical Guideline
7%
Colon Diverticulosis
15%
Colonoscopy
7%
Colorectal Cancer
19%
Colorectal Disease
7%
Cytoreductive Surgery
100%
Diagnosis
9%
Disease
8%
Diverticulitis
24%
Diverticulum
7%
Emergency Department
8%
Germline Mutation
8%
Hepatectomy
9%
Hepatocellular Carcinoma
22%
Hyperthermic Intraperitoneal Chemotherapy
94%
Intraperitoneal Chemotherapy
19%
Liver Enzyme
7%
Liver Transplantation
10%
Long Term Survival
9%
Lymph Node Metastasis
7%
Lymphocyte
8%
Malignant Neoplasm
19%
Metastasectomy
9%
Metastatic Carcinoma
9%
Monocyte
7%
Neoplasm
20%
Neutrophil
8%
Ovarian Cancer
7%
Overall Survival
20%
Pancreaticoduodenectomy
15%
Peritoneum Cancer
12%
Peritoneum Mesothelioma
30%
Peritoneum Metastasis
26%
Platelet
8%
Programmed Death 1 Ligand 1
7%
Propensity Score Matching
10%
Recurrent Disease
7%
Sorafenib
8%
Stoma
7%
Stomach Cancer
8%
Surgery
18%
Venous Thromboembolism
7%
Keyphrases
Acute Appendicitis
15%
Acute Diverticulitis
19%
Adenocarcinoma
7%
Appendiceal
15%
Appendiceal Neoplasms
8%
CA-125 Levels
15%
Carbohydrate Antigen 125 (CA125)
20%
Chemotherapy Outcomes
7%
Colonic Diverticulitis
15%
Colorectal Cancer
10%
Confidence Interval
9%
Cytoreductive Surgery
95%
Diverticulitis
10%
Germline mutation
8%
Goblet
7%
Hepatocellular Carcinoma
15%
Hidden Danger
7%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
94%
Intraductal
7%
Intraperitoneal Chemotherapy
10%
Laparoscopic Pancreaticoduodenectomy
15%
Liver Involvement
7%
Liver Resection
8%
Liver Transplantation
9%
Locoregional Therapy
7%
Long-term Survival
8%
Lymph Node Metastasis
7%
Malignant Peritoneal Mesothelioma
8%
Median Overall Survival
8%
Metastasectomy
9%
National Surgical Quality Improvement Program (NSQIP)
15%
Neoplasms
7%
Overall Survival
10%
Pancreaticoduodenectomy
8%
Patient Selection
8%
Peritoneal Cancer Index
17%
Peritoneal Carcinomatosis
17%
Peritoneal Mesothelioma
22%
Peritoneal Metastasis
26%
Peritoneal Surface Malignancy
16%
Postoperative Outcomes
9%
Postoperative Pancreatic Fistula
8%
Propensity Score Matching
16%
Readmission
10%
Serum CA125
7%
Socioeconomic Factors
8%
Sorafenib
8%
Systemic Chemotherapy
20%
Systemic Recurrence
7%
Total Bilirubin
7%